N-(2-(Benzo[b]thiophen-5-ylmethanesulfonyl)-1-(2,3-dihydrobenzo[1,4]dioxin-6-yl)-ethyl]-N-hydroxyformamide | 376387-01-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: N-(2-(Benzo[b]thiophen-5-ylmethanesulfonyl)-1-(2,3-dihydrobenzo[1,4]dioxin-6-yl)-ethyl]-N-hydroxyformamide
• 英文别名: N-[2-(1-benzothiophen-5-ylmethylsulfonyl)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-N-hydroxyformamide
• CAS: 376387-01-8
• 化学式: C₂₀H₁₉NO₆S₂
• 分子量: 433.506
• InChiKey: FDTPHVDPRWDAAT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  130
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides
  申请人：——

  公开号：US20040024066A1

  公开（公告）日：2004-02-05

  Compounds of formula (I): 1 R is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl; and R 1 is bicyclyl or heterobicyclyl, are useful in the treatment and prophylaxis of conditions mediated by s-CD23.

  式(I)的化合物：1R是氢，烷基，烯基，炔基，芳基，杂芳基或杂环烷基；和R1是双环烷基或杂双环烷基，对由s-CD23介导的疾病的治疗和预防具有用处。
• Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides
  申请人：Best John Desmond

  公开号：US20050288376A1

  公开（公告）日：2005-12-29

  Compounds of formula (I): R is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl; and R 1 is bicyclyl or heterobicyclyl, are useful in the treatment and prophylaxis of conditions mediated by s-CD23.

  式(I)的化合物： 其中R为氢、烷基、烯基、炔基、芳基、杂芳基或杂环基； R1为双环或杂双环基， 可用于治疗和预防由s-CD23介导的疾病。
• BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP1289980A1

  公开（公告）日：2003-03-12
• [EN] BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES<br/>[FR] N-HYDROXYFORMAMIDES A SUBSTITUTION BICYCLYLE OU HETEROBICYCLYLMETHANESULFONYLAMINO
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO2001090100A1

  公开（公告）日：2001-11-29

  Compounds of formula (I): R is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl; and R1 is bicyclyl or heterobicyclyl, are useful in the treatment and prophylaxis of conditions mediated by s-CD23.